Comparative Pharmacology
Head-to-head clinical analysis: AFRINOL versus SUDAFED 12 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFRINOL versus SUDAFED 12 HOUR.
AFRINOL vs SUDAFED 12 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Afrinol is a sympathomimetic amine that acts as a nasal decongestant by stimulating alpha-1 adrenergic receptors in the vascular smooth muscle of nasal blood vessels, causing vasoconstriction and reducing nasal congestion. It also has weak alpha-2 agonist activity.
Pseudoephedrine is a sympathomimetic amine that acts as an agonist at alpha-1 and alpha-2 adrenergic receptors, causing vasoconstriction of nasal mucosa and reducing nasal congestion.
Oral: 1 tablet (pseudoephedrine 120 mg, triprolidine 2.5 mg) every 12 hours; maximum 2 tablets per day.
120 mg orally every 12 hours, extended-release tablets. Maximum 240 mg per day.
None Documented
None Documented
9–11 hours in healthy adults; prolonged to 16–18 hours in hepatic cirrhosis and up to 20 hours in severe renal impairment. Clinical context: dosing interval typically 12 hours in normal renal function.
8-10 hours in adults with normal renal function; prolonged to 19-24 hours in renal impairment (CrCl <30 mL/min); shorter in children (3-4 hours)
Renal (approximately 70–90% as unchanged drug and metabolites), with about 10% biliary/fecal elimination. Dose adjustment required in renal impairment (CrCl <30 mL/min).
Renal: 74-95% as unchanged drug; 1-4% as active metabolite (norpsuedoephedrine); biliary/fecal: minimal (<1%)
Category C
Category C
Decongestant
Decongestant